IDEXX Laboratories, Inc.

Valuation Analysis

About the Company

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Coliler

IDEXX Laboratories, Inc. Stock at a Glance

IDEXX Laboratories, Inc. (IDXX) is currently trading at $560.88 with a market capitalization of $44.2B. The trailing P/E ratio stands at 41.33x, with a forward P/E of 33.96x. The 52-week range spans from $506.91 to $769.98; the current price is 27.2% below the yearly high. Year-over-year revenue growth stands at +14.3%. The net profit margin stands at 24.63%.

💰 Dividend

IDEXX Laboratories, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

14 analysts rate IDEXX Laboratories, Inc. (IDXX) on consensus: Buy. The average price target is $709.14, implying +26.43% from the current price. Analyst price targets range from $470.00 to $805.00.

IDEXX Laboratories, Inc.: The Investment Case in Detail

IDEXX Laboratories, Inc. (IDXX) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 14.3% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 62.05%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 72.91% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.

The Bear Case

Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

At a PEG of 3.59, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 29.21x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

What to Watch Next

• The forward P/E of 33.96x is meaningfully below the trailing 41.33x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 26.43% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to above-average price swings.

Trading Data

Related Stocks in the Same Sector

Where can I buy IDEXX Laboratories, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.